<1-hydroxy-2-(5,6,7,8-tetrahydroimidazo<1,2-a>pyridin-3-yl)ethylidene>bisphosphonic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: <1-hydroxy-2-(5,6,7,8-tetrahydroimidazo<1,2-a>pyridin-3-yl)ethylidene>bisphosphonic acid
• 英文别名: [1-Hydroxy-1-phosphono-2-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-3-yl)ethyl]phosphonic acid
• 化学式: C₉H₁₆N₂O₇P₂
• 分子量: 326.183
• InChiKey: GFNQNTWQTPJYAX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.2
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  153
• 氢给体数：
  5
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  咪唑并[1,2-a]吡啶-3-乙酸 在 platinum(IV) oxide 盐酸 、 亚磷酸 、 氢气 、 三氯化磷 作用下， 反应 1.5h， 生成 <1-hydroxy-2-(5,6,7,8-tetrahydroimidazo<1,2-a>pyridin-3-yl)ethylidene>bisphosphonic acid
  参考文献：
  名称：

  Studies on Novel Bone Resorption Inhibitors. II. Synthesis and Pharmacological Activities of Fused Aza-heteroarylbisphosphonate Derivatives.

  摘要：

  我们合成了两个新系列的融合杂己基双膦酸盐（5、8），它们在结构上与incadronate（YM175）和相关化合物有很大不同，并利用甲状旁腺激素（PTH）诱导的大鼠高钙血症模型（PIH 模型）对它们的抗骨吸收活性进行了评估。在这些化合物中，有几种表现出比帕米膦酸钠更强的抗骨吸收活性。其中，[1-羟基-2-（咪唑并[1，2-α]吡啶-3-基）亚乙基]双膦酸（5b，minodronate）不仅在 PIH 模型中，而且在大鼠固定骨萎缩模型（DA 模型）中的活性都比帕米膦酸高出 100 倍，因此被选中用于临床开发。本文讨论了这些新系列双膦酸盐的结构-活性关系。

  DOI：

  10.1248/cpb.46.1703

文献信息

• Preservative system for acidic beverages based on sequestrants
  申请人：PepsiCo, Inc.

  公开号：US10631557B2

  公开（公告）日：2020-04-28

  The present invention provides beverage preservative systems for use in high acid beverage products, and beverage products comprising the beverage preservative systems. The beverage preservative system prevents spoilage by microorganisms in a beverage within a sealed container for a period of at least 16 weeks. The present invention reduces or eliminates the use of conventional preservatives that pose health and/or environmental concerns. The components that make up the beverage preservative system of invention work together in a synergistic manner to reduce the amount of preservative required and so improve the inventive beverage's sensory impact over beverages having conventional preservatives.

  本发明提供了用于高酸饮料产品的饮料防腐剂系统，以及包含该饮料防腐剂系统的饮料产品。饮料防腐剂系统可防止密封容器中的饮料在至少 16 周的时间内因微生物而变质。本发明减少或消除了对健康和/或环境造成影响的传统防腐剂的使用。构成本发明饮料防腐剂系统的各种成分以协同增效的方式共同发挥作用，减少了所需的防腐剂用量，因此与使用传统防腐剂的饮料相比，本发明饮料的感官效果更好。
• Preservative System For Acidic Beverages Based On Sequestrants
  申请人：Smith Richard T.

  公开号：US20100166917A1

  公开（公告）日：2010-07-01

  The present invention provides beverage preservative systems for use in high acid beverage products, and beverage products comprising the beverage preservative systems. The beverage preservative system prevents spoilage by microorganisms in a beverage within a sealed container for a period of at least 16 weeks. The present invention reduces or eliminates the use of conventional preservatives that pose health and/or environmental concerns. The components that make up the beverage preservative system of invention work together in a synergistic manner to reduce the amount of preservative required and so improve the inventive beverage's sensory impact over beverages having conventional preservatives.
• US9560871B2
  申请人：——

  公开号：US9560871B2

  公开（公告）日：2017-02-07
• [EN] PRESERVATIVE SYSTEM FOR ACIDIC BEVERAGES BASED ON SEQUESTRANTS<br/>[FR] SYSTÈME DE CONSERVATEUR POUR DES BOISSONS ACIDES À BASE DE SÉQUESTRANTS
  申请人：PEPSICO INC

  公开号：WO2010078069A1

  公开（公告）日：2010-07-08

  The present invention provides beverage preservative systems for use in high acid beverage products, and beverage products comprising the beverage preservative systems. The beverage preservative system prevents spoilage by microorganisms in a beverage within a sealed container for a period of at least 16 weeks. The present invention reduces or eliminates the use of conventional preservatives that pose health and/or environmental concerns. The components that make up the beverage preservative system of invention work together in a synergistic manner to reduce the amount of preservative required and so improve the inventive beverage's sensory impact over beverages having conventional preservatives.
• Studies on Novel Bone Resorption Inhibitors. II. Synthesis and Pharmacological Activities of Fused Aza-heteroarylbisphosphonate Derivatives.
  作者：Makoto TAKEUCHI、Shunichi SAKAMOTO、Kousei KAWAMUKI、Hiroyuki KURIHARA、Hideaki NAKAHARA、Yasuo ISOMURA

  DOI：10.1248/cpb.46.1703

  日期：——

  Two new series of fused aza-heteroarylbisphosphonates (5, 8), which are structurally quite different from incadronate (YM175), and related compounds were synthesized and evaluated for antiresorptive activity using a parathyroid hormone (PTH)-induced hypercalcemia model in rats (PIH model). Among these compounds, several exhibited more potent antiresorptive activity than pamidronate. In particular, [1-hydroxy-2-(imidazo[1, 2-α]pyridin-3-yl)ethylidene]bisphosphonic acid (5b, minodronate) was 100-fold more potent than pamidronate in not only the PIH model, but also in an immobilization bone atrophy model in rats (DA model), and was selected for clinical development. The structure-activity relationships in these new series of bisphosphonates are discussed.

  我们合成了两个新系列的融合杂己基双膦酸盐（5、8），它们在结构上与incadronate（YM175）和相关化合物有很大不同，并利用甲状旁腺激素（PTH）诱导的大鼠高钙血症模型（PIH 模型）对它们的抗骨吸收活性进行了评估。在这些化合物中，有几种表现出比帕米膦酸钠更强的抗骨吸收活性。其中，[1-羟基-2-（咪唑并[1，2-α]吡啶-3-基）亚乙基]双膦酸（5b，minodronate）不仅在 PIH 模型中，而且在大鼠固定骨萎缩模型（DA 模型）中的活性都比帕米膦酸高出 100 倍，因此被选中用于临床开发。本文讨论了这些新系列双膦酸盐的结构-活性关系。